perspectives on the checkmate 9la study
Published 4 years ago • 206 plays • Length 2:28Download video MP4
Download video MP3
Similar videos
-
7:16
checkmate 9la study: nivo ipi in nsclc
-
3:30
checkmate 9la: tmb and immune checkpoint inhibitor efficacy
-
8:03
checkmate-9la: histology and frontline impact
-
5:43
checkmate 9la trial on nivolumab plus ipilimumab for nsclc
-
1:22
dr. reck on safety data from the checkmate-9la trial in metastatic/recurrent nsclc
-
10:46
the checkmate 9la trial for stage iv/recurrent non-small cell lung cancer
-
6:03
checkmate 9la: nivolumab, ipilimumab and chemotherapy for stage iv nsclc
-
22:47
friday beyond spotlights ep 5 professor tony mok: the place to be for cancer research & life science
-
2:44
cancer immunotherapy with nivolumab plus ipilimumab vs. chemotherapy: insights from checkmate 227
-
4:46
5-year survival outcomes from the pacific trial
-
2:35
checkmate-816: what does the data tell us?
-
2:21
expert comment: the checkmate 227 study | sanjay popat
-
2:31
highlights in nsclc from wclc 2021
-
10:46
the checkmate 9la trial for stage iv/recurrent non-small cell lung cancer
-
2:08
dr. porter on the 3-year follow-up data from the checkmate-9la trial in nsclc
-
1:44
checkmate 649: nivolumab and chemotherapy or ipilimumab in gc/gejc/eac
-
1:06
dr. patrick m. forde on next steps after failed checkmate-026 study in nsclc
-
2:07
checkmate 816: addressing unanswered questions on surgical outcomes following neoadjuvant chemo-io
-
2:01
checkmate-722: investigating the addition of immunotherapy to chemotherapy in egfr-mutant nsclc
-
2:01
upcoming nsclc trials in 2022: checkmate 816 & keynote-091
-
2:06
checkmate-743 study in mesothelioma
-
1:58
dr. plimack on significance of checkmate-025 trial in rcc